Attempted validation of the NUn score and inflammatory markers as predictors of esophageal anastomotic leak and major complications.
Findlay JM. et al, (2015), Dis Esophagus, 28, 626 - 633
Attempted validation of the NUn score and inflammatory markers as predictors of esophageal anastomotic leak and major complications
Findlay JM. et al, (2015), Diseases of the Esophagus, 28, 626 - 633
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Ahmad SS. et al, (2015), Melanoma Res, 25, 432 - 442
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Middleton MR. et al, (2015), Ann Oncol, 26, 2173 - 2179
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression.
Mura M. et al, (2015), Oncogene, 34, 5025 - 5036
The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5'TOP sequence.
Lahr RM. et al, (2015), Nucleic Acids Res, 43, 8077 - 8088
Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?
Afshar M. et al, (2015), Cancer Investigation, 33, 347 - 353
Focal segmental glomerulosclerosis in a patient with mantle cell lymphoma.
Hindocha S. et al, (2015), BMJ Case Rep, 2015
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
middleton MR. et al, (2015), British Journal of Cancer
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
Middleton M., (2015), British Journal of Cancer
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
Collins GP. et al, (2015), Br J Haematol, 170, 886 - 890
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
Stratigos A. et al, (2015), Eur J Cancer, 51, 1989 - 2007
Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE)
Middleton M. et al, (2015), EUROPEAN JOURNAL OF CANCER, 51, S678 - S679
Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
Rasco DW. et al, (2015), EUROPEAN JOURNAL OF CANCER, 51, S53 - S54
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse
Clark L. et al, (2015), EUROPEAN JOURNAL OF CANCER, 51, S686 - S686
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RHI. et al, (2015), J Clin Oncol, 33, 2780 - 2788
Pyrimidine derivatives and guanine derivatives, and their use in treating tumour cells
McMurry TBH. et al, (2015)
A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
Middleton MR. et al, (2015), CANCER RESEARCH, 75
Clinical potential of pacritinib in the treatment of myelofibrosis.
Duenas-Perez AB. and Mead AJ., (2015), Ther Adv Hematol, 6, 186 - 201
Immune checkpoint inhibition in lymphoid disease.
Eyre TA. and Collins GP., (2015), Br J Haematol, 170, 291 - 304